While blocking glutamine metabolism in combination with PD-1/PD-L1 inhibitors significantly boosts T cell anti-tumor activity in vitro and in vivo in tumor cells with primary resistance (low PD-L1 expression) (191), this approach may not be effective for immunotherapy in “hot” tumors that already exhibit high PD-L1 expression. Here, CD274 is linked to neoplasm.